Pomerantz LLP has initiated a securities investigation on behalf of Danone S.A. investors following the company's disclosure of contaminated infant formula batches sourced from Thailand. The investigation focuses on potential securities fraud claims related to the discovery of cereulide, a toxic bacterial byproduct, detected in Danone's Dumex Dulac 1 formula line.
The contamination announcement triggered notable market volatility for Danone's American Depositary Receipts (ADRs). The stock declined 7.95% on January 21, 2026, the trading day following the public disclosure, with an additional 2.7% decline recorded on January 23, 2026. The cumulative losses reflect investor concerns regarding the company's quality control procedures and potential liability exposure.
The investigation will examine whether company management possessed knowledge of contamination risks prior to public disclosure and whether adequate disclosures were made to investors in a timely manner. Cereulide, the detected cytotoxin, poses health risks particularly to infants and has prompted regulatory scrutiny of the affected product batches and broader supply chain controls.